Drug intelligence / Profile preview

botensilimab + balstilimab + agenT-797

Development stage: Phase 2
Lead developer: Agenus
Modality: Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Botensilimab + balstilimab + agenT-797 is an investigational combination immunotherapy regimen consisting of three distinct agents: botensilimab (an Fc-enhanced IgG1 monoclonal antibody targeting CTLA-4), balstilimab (a fully human IgG4 monoclonal antibody targeting PD-1), and agenT-797 (an allogeneic, off-the-shelf invariant natural killer T [iNKT] cell therapy). Developed by Agenus and its spinout MiNK Therapeutics, this combination is designed to overcome resistance to standard checkpoint inhibition by combining dual checkpoint blockade with innate and adaptive immune activation. The regimen is currently being evaluated in investigator-initiated Phase II clinical trials, including studies for previously treated, PD-1-refractory advanced gastroesophageal cancers (in combination with ramucirumab and paclitaxel) and previously treated microsatellite-stable (pMMR) metastatic colorectal cancer with liver metastases.

Other names: AGEN1181 + AGEN2034 + MiNK-797AGEN1181 + AGEN2034 + agenT-797BOT + BAL + agenT-797BOT/BAL/agenT-797agenT-797 + botensilimab + balstilimabbalstilimab + botensilimab + agenT-797botensilimab + balstilimab + agenT-797

Targets

CD80 (T-lymphocyte activation antigen CD80)CD86 (T-lymphocyte activation antigen CD86)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)PDCD1LG2 (Programmed cell death 1 ligand 2)

Beyond the preview

Go deeper on botensilimab + balstilimab + agenT-797.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on botensilimab + balstilimab + agenT-797.